⚠ For Research Use Only. Not for human or veterinary therapeutic use. Handle under appropriate biosafety precautions.
Overview
Tylosin Tartrate is a water-soluble salt form of Tylosin, a naturally occurring macrolide antibiotic produced by Streptomyces fradiae. It exerts its antimicrobial effect by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. Tylosin Tartrate is primarily active against Gram-positive bacteria and select Gram-negative and mycoplasmal organisms.
The tartrate salt form offers superior aqueous solubility compared to the free base, making it particularly suitable for preparation of liquid culture media, antimicrobial susceptibility testing solutions, and selective agar formulations. AuSaMicS supplies Tylosin Tartrate at research grade (≥ 95% purity) with full batch traceability and Certificate of Analysis.
Chemical Identity
| Product Name |
Tylosin Tartrate |
| Chemical Name |
Tylosin, (2R,3R)-2,3-dihydroxybutanedioate (salt) |
| Molecular Formula |
C₄₆H₇₇NO₁₇ · C₄H₆O₆ |
| Molecular Weight |
1,154.32 g/mol |
| CAS No. |
74610-55-2 |
| Catalog No. |
ASA-2056 |
| Appearance |
White to off-white powder |
| Antibiotic Class |
Macrolide |
| Source Organism |
Streptomyces fradiae |
| Mechanism of Action |
Inhibits protein synthesis — binds bacterial 50S ribosomal subunit |
| Spectrum |
Gram-positive bacteria; select Gram-negative; Mycoplasma spp. |
| Grade |
Research Grade |
| Purity |
≥ 95% |
Applications
🧪
Resistance Research
Studies on macrolide resistance mechanisms, efflux pumps, and ribosomal modification in bacterial strains.
🔬
Selective Media
Selective agent in microbiological culture media for isolation of resistant or target organisms from mixed populations.
📋
Susceptibility Testing
Antimicrobial susceptibility testing (AST) — MIC determination, disk diffusion, and broth microdilution assays.
Additional applications include veterinary and agricultural research studies, gut microbiome modulation research, and as a reference standard in analytical method development.
Packaging
| Available Sizes |
1 g · 5 g · 10 g · Bulk quantities on request |
| Container |
Amber glass vial or sealed HDPE container |
| Labelling |
Batch number, CAS, purity, storage conditions, safety warnings |
Storage & Stability
| Storage |
Cool, dry place; protected from light; tightly closed |
| Recommended Temp. |
2–8 °C (refrigerator) for long-term storage; RT acceptable short-term |
| Shelf Life |
See retest date on label; typically 3 years from manufacture under correct conditions |
| Solution Stability |
Prepare fresh aqueous solutions; store at 4 °C for up to 2 weeks; freeze at −20 °C for longer storage |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · For research use only. Not for human or veterinary therapeutic use. · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
Product Identification
| Product Name |
Tylosin Tartrate |
| Cat No. |
ASA-2056 |
| CAS No. |
74610-55-2 |
| Antibiotic Class |
Macrolide |
| Grade |
Research Grade |
| Purity |
≥ 95% |
| Pack Sizes |
1 g · 5 g · 10 g · Bulk |
Physical Properties
| Appearance |
White to off-white powder |
| Molecular Formula |
C₄₆H₇₇NO₁₇ · C₄H₆O₆ |
| Molecular Weight |
1,154.32 g/mol |
| Solubility (water) |
Soluble — enhanced vs. free base |
| Solubility (MeOH) |
Soluble |
| UV Absorption |
~290 nm (characteristic macrolide) |
| Storage |
2–8 °C, dark, dry |
Mechanism of Action
| Target |
Bacterial 50S ribosomal subunit (23S rRNA) |
| Action |
Inhibits protein synthesis by blocking translocation and peptidyl transfer |
| Spectrum |
Primarily Gram-positive bacteria; some Gram-negative; Mycoplasma, Ureaplasma spp. |
| Bacteriostatic / cidal |
Primarily bacteriostatic at standard concentrations |
| Resistance Mechanism |
Ribosomal methylation (erm genes); efflux pumps (mef genes); enzymatic inactivation |
Preparation Guidelines
| Stock Solution |
Dissolve in sterile water or methanol at 10–50 mg/mL; vortex until clear; filter through 0.22 µm |
| Working Concentration |
Typical MIC range: 0.5–64 µg/mL depending on organism |
| Media Supplementation |
Add aseptically after autoclaving at 45–50 °C; avoid prolonged heat exposure |
| pH Stability |
Stable pH 4–8; avoid strongly acidic or alkaline conditions |
| Incompatibilities |
Strong oxidising agents; avoid prolonged exposure to high temperatures |
Quality Control Specifications
| Parameter |
Specification |
Method |
| Appearance |
White to off-white powder; no visible impurities |
Visual inspection |
| Purity (HPLC) |
≥ 95% |
HPLC (reversed phase, UV 290 nm) |
| Identity |
Confirmed by UV-Vis and MS |
UV-Vis / LC-MS |
| Loss on Drying |
≤ 5.0% w/w |
105 °C / 2 h (gravimetric) |
| Solubility |
Clear solution at 10 mg/mL in water |
Solution test |
| Biological Activity |
Inhibition zone ≥ 18 mm vs. S. aureus ATCC 25923 (disk diffusion) |
Kirby-Bauer disk diffusion |
| Heavy Metals |
≤ 20 ppm (Pb equiv.) |
ICP-MS |
Technical References
| Antibiotic Class |
Macrolide — 16-membered lactone ring; produced by Streptomyces fradiae
|
| Clinical Relevance |
Veterinary macrolide antibiotic; model compound for macrolide resistance studies |
| CLSI / EUCAST |
Reference breakpoints available for susceptibility testing (veterinary organisms) |
| Related Compounds |
Tylosin A (major), Tylosin B (Desmycosin), Tylosin C, Tylosin D |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074 · support@ausamics.com · www.ausamics.com.au
Safety Data Sheet — GHS Format (Australian WHS Regulations 2017)
Issue Date: March 2026 · Rev: 1.0
Section 1 — Identification
| Product Name |
Tylosin Tartrate — ASA-2056 |
| CAS No. |
74610-55-2 |
| Intended Use |
Research reagent — antimicrobial agent for laboratory use only |
| Supplier |
AuSaMicS Pty Ltd, 31 Longview CT, Thomastown VIC 3074, Australia |
| Phone / Emergency |
+61 412 520 598 · Poisons Centre: 13 11 26 (24h) |
| Email / Web |
support@ausamics.com · www.ausamics.com.au |
Section 2 — Hazard Identification
| GHS Classification |
H317: May cause allergic skin reaction (sensitiser). H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| Signal Word |
Warning |
| Hazard Statements |
H317 · H334 — sensitisation risk for beta-lactam/macrolide-sensitive individuals |
| Precautionary |
P260 · P272 · P280 · P284 · P302+P352 · P342+P311 · P501 |
| Antibiotic Hazard |
Contains active antibiotic — avoid unnecessary environmental release; do not discharge to drains without inactivation |
| Sensitisation |
Macrolide antibiotics are known sensitisers — personnel with known macrolide hypersensitivity should avoid handling |
Section 3 — Composition
| Component |
CAS No. |
Proportion |
GHS Classification |
| Tylosin Tartrate |
74610-55-2 |
≥ 95% |
H317 · H334 |
| Related macrolide impurities |
— |
≤ 5% |
Not classified at supplied levels |
Sections 4–8 — First Aid, Fire, Spill, Handling, PPE
| Inhalation |
Remove to fresh air. If allergic response or difficulty breathing develops, seek immediate medical attention. Note: macrolide sensitiser — H334. |
| Skin Contact |
Wash with soap and water ≥ 15 min. H317 — may cause allergic reaction in sensitised individuals. Seek medical advice if reaction occurs. |
| Eye Contact |
Rinse with copious water ≥ 15 min. Seek medical attention if irritation persists. |
| Ingestion |
Do not induce vomiting. Rinse mouth. Seek medical advice. Active antibiotic — inform physician of substance. |
| Fire |
Not flammable. CO, CO₂, NOₓ on combustion. Use CO₂ or dry chemical extinguisher. |
| Spill |
Collect carefully; avoid dust. Decontaminate area with 1% NaOH or bleach solution to inactivate antibiotic. Dispose per Section 13. |
| Respiratory PPE |
FFP2/P2 respirator when handling powder — macrolide sensitiser risk |
| Hand Protection |
Nitrile gloves — change immediately if contaminated |
| Eye / Face |
Safety glasses; goggles if powder generation risk |
| Body Protection |
Lab coat; closed footwear |
| Engineering Controls |
Handle in fume hood or with local exhaust ventilation; avoid open-bench powder weighing |
Sections 9–16 — Properties, Stability, Toxicology, Disposal, Regulatory
| Physical State |
Solid (powder); white to off-white |
| Solubility |
Soluble in water and methanol |
| Stability |
Stable at 2–8 °C, dark, dry. Degrades in strongly acidic/alkaline conditions. |
| Skin Sensitisation |
H317 — macrolide class sensitiser |
| Respiratory Sensitisation |
H334 — may cause asthma/allergy symptoms on inhalation |
| Antibiotic Resistance Risk |
Contains active macrolide antibiotic — inactivate before environmental disposal to prevent resistance selection |
| Aquatic Toxicity |
Antibiotics are potentially harmful to aquatic microbial communities — prevent discharge to waterways |
| Waste Disposal |
Inactivate with 1% NaOH (pH >10, 30 min) or autoclave 121 °C / 30 min before disposal. Dispose via licensed chemical waste contractor. Do NOT discharge active antibiotic to drain. |
| Transport |
Not classified as dangerous goods (ADG/IATA/IMDG) in standard laboratory quantities |
| AICS (Australia) |
Listed on Australian Inventory of Chemical Substances |
| SUSMP Schedule |
Schedule 4 (Prescription Only Medicine) for therapeutic use — this supply is for research use only |
| WHS Regulations |
H317/H334 — hazardous chemical under WHS Regulations 2017; risk assessment required |
| SDS Prepared By |
AuSaMicS Pty Ltd — Technical & Quality Department · March 2026 · Rev 1.0 |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
For research use only. Not for human or veterinary therapeutic use.
Product Details
| Product Name |
Tylosin Tartrate |
| Catalog No. |
ASA-2056 |
| CAS No. |
74610-55-2 |
| Lot No. |
TYL260301 |
| Mfg. Date |
March 2026 |
| Retest Date |
March 2029 |
| Grade |
Research Grade |
Document Information
| COA No. |
COA-ASA-2056-L001 |
| Issue Date |
March 2026 |
| Issued By |
AuSaMicS Quality Control |
| Test Ref. |
In-house / USP / CLSI |
Test Results & Analytical Data
| Test Parameter |
Specification |
Method |
Result |
Status |
| Appearance |
White to off-white powder; no visible impurities |
Visual inspection |
Conforms |
PASS |
| Identity (UV-Vis) |
Absorption maximum ~290 nm (macrolide characteristic) |
UV-Vis spectrophotometry |
289 nm |
PASS |
| Purity (HPLC) |
≥ 95% |
HPLC reversed phase, UV 290 nm |
97.2% |
PASS |
| Loss on Drying |
≤ 5.0% w/w |
105 °C / 2 h (gravimetric) |
2.8% |
PASS |
| Solubility (10 mg/mL, water) |
Clear solution; complete dissolution |
Solution test |
Clear |
PASS |
| Biological Activity (disk diffusion) |
Inhibition zone ≥ 18 mm vs. S. aureus ATCC 25923 |
Kirby-Bauer disk diffusion |
22 mm |
PASS |
| Heavy Metals (Pb equiv.) |
≤ 20 ppm |
ICP-MS |
< 5 ppm |
PASS |
| CAS Identity Verification |
CAS 74610-55-2 confirmed |
LC-MS comparison vs. reference |
Confirmed |
CONFORM |
Conclusion: Lot TYL260301 fully meets all release specifications for Tylosin Tartrate (CAS 74610-55-2). Purity 97.2% (≥ 95% spec.), biological activity confirmed. This lot is RELEASED for research use.
Quality Control Analyst
AuSaMicS Quality Control Department
Date: March 2026 | Signature: _______________
Quality Manager
AuSaMicS Pty Ltd
Date: March 2026 | Signature: _______________
AuSaMicS Pty Ltd (ABN 56 676 640 467) warrants this product meets specifications at time of manufacture. For research use only. Not for human or veterinary therapeutic use. Results specific to Lot TYL260301 only. · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au